{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=48",
    "query": {
      "condition": "Advanced Malignancy",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 9813,
    "total_pages": 982,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T21:06:27.009Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02989636",
      "title": "Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chordoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-03-10",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02989636"
    },
    {
      "nct_id": "NCT00616564",
      "title": "Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mt. Sinai Medical Center, Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "16 Years to 90 Years"
      },
      "enrollment_count": 36,
      "start_date": "2006-02",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-05-03",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 2,
      "location_summary": "Miami Beach, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616564"
    },
    {
      "nct_id": "NCT00633087",
      "title": "A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "2-deoxyglucose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2006-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00633087"
    },
    {
      "nct_id": "NCT00804336",
      "title": "Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid Tumor",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "SOM230",
          "type": "DRUG"
        },
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2008-10",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00804336"
    },
    {
      "nct_id": "NCT03695471",
      "title": "Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Sezary Syndrome",
        "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-02-04",
      "completion_date": "2024-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695471"
    },
    {
      "nct_id": "NCT01279798",
      "title": "Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lucanix® (belagenpumatucel-L)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NovaRx Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-01",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01279798"
    },
    {
      "nct_id": "NCT03764293",
      "title": "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced or Metastatic and Unresectable HCC"
      ],
      "interventions": [
        {
          "name": "SHR-1210",
          "type": "DRUG"
        },
        {
          "name": "Apatinib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu HengRui Medicine Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 543,
      "start_date": "2019-06-10",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • La Jolla, California • Orange, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03764293"
    },
    {
      "nct_id": "NCT05355753",
      "title": "A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Synovial Sarcoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "CFT8634",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "C4 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2022-03-25",
      "completion_date": "2023-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-12-17",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Santa Monica, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05355753"
    },
    {
      "nct_id": "NCT07287995",
      "title": "A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP2998",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2026-02-05",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 5,
      "location_summary": "Celebration, Florida • Hackensack, New Jersey • New Hyde Park, New York + 2 more",
      "locations": [
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287995"
    },
    {
      "nct_id": "NCT07644039",
      "title": "Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "PM54",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2026-05-21",
      "completion_date": "2029-04-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-03T21:06:27.009Z",
      "location_count": 6,
      "location_summary": "New York, New York • Fort Worth, Texas • Houston, Texas + 2 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07644039"
    }
  ]
}